History of the Hatch-Waxman Act.

被引：0

|

作者：

Leeds, J ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Associate Gen Patent Counsel, Indianapolis, IN 46285 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2004年 / 228卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

009-CHAL

引用

收藏

页码：U396 / U397

页数：2

相关论文

共 50 条

[21] Overview of the Hatch-Waxman Act and its impact on the drug development process
Mossinghoff, GJ
[J]. FOOD AND DRUG LAW JOURNAL, 1999, 54 (02) : 187 - 194
[22] Study recommends changes to Hatch-Waxman
不详
[J]. PHARMACEUTICAL PATENT ANALYST, 2012, 1 (01) : 20 - 20
[23] Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984
Boehm, Garth
Yao, Lixin
Han, Liang
Zheng, Qiang
[J]. ACTA PHARMACEUTICA SINICA B, 2013, 3 (05) : 297 - 311
[24] PERSONAL JURISDICTION IN HATCH-WAXMAN CASES
Marusak, Michael
[J]. CATHOLIC UNIVERSITY LAW REVIEW, 2016, 66 (01): : 189 - 222
[25] Biosimilars: impact of differences with Hatch-Waxman
Kowalchyk, Katherine
Crowley-Weber, Cara
[J]. PHARMACEUTICAL PATENT ANALYST, 2013, 2 (01) : 29 - 37
[26] Correcting Hatch-Waxman: An author responds
Birndt, Ernst R.
[J]. HEALTH AFFAIRS, 2008, 27 (03) : 903 - 903
[27] Toward a Centralized Hatch-Waxman Venue
Makowski, Matthew
[J]. UNIVERSITY OF CHICAGO LAW REVIEW, 2022, 89 (07): : 1837 - 1870
[28] 美国Hatch-Waxman法案研究
王鑫
甄橙
[J]. 东岳论丛, 2017, 38 (01) : 165 - 173
[29] DELAYED ACCESS TO GENERIC MEDICINE: A COMMENT ON THE HATCH-WAXMAN ACT AND THE "APPROVAL BOTTLENECK"
Patel, Ankur N.
[J]. FORDHAM LAW REVIEW, 2009, 78 (02) : 1075 - 1115
[30] Patent term extensions for human drugs under the US Hatch-Waxman Act
Boone, Jeffrey S.
[J]. JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2009, 4 (09) : 658 - 664

← 1 2 3 4 5 →